NZ629996A - 2’- substituted carba-nucleoside analogs for antiviral treatment - Google Patents

2’- substituted carba-nucleoside analogs for antiviral treatment

Info

Publication number
NZ629996A
NZ629996A NZ629996A NZ62999613A NZ629996A NZ 629996 A NZ629996 A NZ 629996A NZ 629996 A NZ629996 A NZ 629996A NZ 62999613 A NZ62999613 A NZ 62999613A NZ 629996 A NZ629996 A NZ 629996A
Authority
NZ
New Zealand
Prior art keywords
nucleoside analogs
compounds
antiviral treatment
substituted carba
carba
Prior art date
Application number
NZ629996A
Other languages
English (en)
Inventor
Michael O’ Neil Hanrahan Clarke
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NZ629996A publication Critical patent/NZ629996A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12Triazine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/30Vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ629996A 2012-03-13 2013-03-11 2’- substituted carba-nucleoside analogs for antiviral treatment NZ629996A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610411P 2012-03-13 2012-03-13
PCT/US2013/030196 WO2013138236A1 (en) 2012-03-13 2013-03-11 2'- substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
NZ629996A true NZ629996A (en) 2016-10-28

Family

ID=47997868

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629996A NZ629996A (en) 2012-03-13 2013-03-11 2’- substituted carba-nucleoside analogs for antiviral treatment

Country Status (18)

Country Link
US (4) US9481704B2 (enExample)
EP (4) EP3351552B1 (enExample)
JP (3) JP6242378B2 (enExample)
KR (1) KR102068856B1 (enExample)
CN (2) CN106749272B (enExample)
AU (2) AU2013232378B2 (enExample)
CA (1) CA2866381C (enExample)
EA (2) EA028928B9 (enExample)
ES (4) ES2621217T3 (enExample)
IL (2) IL234586A (enExample)
IN (1) IN2014DN08505A (enExample)
MD (1) MD4496C1 (enExample)
MX (1) MX355267B (enExample)
NZ (1) NZ629996A (enExample)
PL (1) PL2834258T3 (enExample)
PT (1) PT2834258T (enExample)
SI (1) SI2834258T1 (enExample)
WO (1) WO2013138236A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
US8633198B1 (en) 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
CA3107640A1 (en) 2011-12-22 2013-06-27 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
ES2621217T3 (es) * 2012-03-13 2017-07-03 Gilead Sciences, Inc. Análogos de carba-nucleósido 2'-sustituidos para tratamiento antivírico
PL2827875T3 (pl) * 2012-03-21 2019-07-31 Janssen Biopharma, Inc. Podstawione nukleozydy, nukleotydy i ich analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
CN106232119B (zh) * 2013-12-11 2021-02-19 河谷控股Ip有限责任公司 A型流感rna-依赖性rna聚合酶的小分子抑制剂
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
CA2945693C (en) * 2014-02-06 2020-06-16 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
JP6671355B2 (ja) 2014-09-26 2020-03-25 リボサイエンス・エルエルシー 呼吸器多核体ウイルスのrna複製の阻害剤としての4’‐ビニル置換ヌクレオシド誘導体
SMT202100592T1 (it) 2014-12-26 2021-11-12 Univ Emory Derivati antivirali della n4-idrossicitidina
RU2720811C2 (ru) 2015-09-23 2020-05-13 Мерк Шарп И Доум Лимитед 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
MY199746A (en) 2017-04-24 2023-11-21 Cocrystal Pharma Inc Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
MX2021000917A (es) 2018-07-27 2021-06-23 Cocrystal Pharma Inc Derivados de pirrolo[2,3-b]piridina como inhibidores de la replicación del virus de la gripe.
ES2937837T3 (es) 2018-09-10 2023-03-31 Cocrystal Pharma Inc Inhibidores de piridopirazina y piridotriazina de la replicación del virus de la gripe
US20220048897A1 (en) 2018-11-26 2022-02-17 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4125810A1 (en) * 2020-03-22 2023-02-08 InspirMed Corp. Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
AU2021245634A1 (en) * 2020-03-30 2022-10-20 Fujifilm Toyama Chemical Co., Ltd. Coronavirus infection treatment drug
CN111956630A (zh) * 2020-08-20 2020-11-20 大连理工大学 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240050362A (ko) * 2021-08-20 2024-04-18 시오노기 앤드 컴파니, 리미티드 바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) * 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5388571A (en) * 1987-07-17 1995-02-14 Roberts; Josephine A. Positive-pressure ventilator system with controlled access for nebulizer component servicing
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
EP0940154B1 (en) * 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US6116234A (en) * 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
CA2426187C (en) * 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
CN1267446C (zh) * 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
JP4398631B2 (ja) 2002-07-12 2010-01-13 富山化学工業株式会社 新規なピラジン誘導体またはその塩並びにそれらを含有する抗ウイルス剤
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
PL2114980T3 (pl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Przeciwwirusowe analogi nukleozydów
AU2008251555B2 (en) * 2007-05-10 2012-08-30 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
WO2009132123A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EP3150608B1 (en) * 2009-09-21 2019-04-10 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ599404A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
US8455451B2 (en) * 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2595980B1 (en) * 2010-07-22 2014-09-03 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
ES2621217T3 (es) 2012-03-13 2017-07-03 Gilead Sciences, Inc. Análogos de carba-nucleósido 2'-sustituidos para tratamiento antivírico

Also Published As

Publication number Publication date
EP3210993A1 (en) 2017-08-30
SI2834258T1 (sl) 2017-04-26
EA028928B9 (ru) 2018-05-31
CN106749272B (zh) 2019-08-30
MD4496B1 (ro) 2017-07-31
EP3351552A1 (en) 2018-07-25
WO2013138236A1 (en) 2013-09-19
EP3351552B1 (en) 2021-05-19
CN106749272A (zh) 2017-05-31
IN2014DN08505A (enExample) 2015-05-15
JP2015509983A (ja) 2015-04-02
ES3005115T3 (en) 2025-03-13
AU2017279590A1 (en) 2018-01-18
US20130243725A1 (en) 2013-09-19
KR102068856B1 (ko) 2020-01-21
JP2017206528A (ja) 2017-11-24
MD20140112A2 (ro) 2015-02-28
CN104185638A (zh) 2014-12-03
EP3932931A1 (en) 2022-01-05
EP3210993B1 (en) 2018-12-12
IL234586A (en) 2017-12-31
MX355267B (es) 2018-04-12
JP6525441B2 (ja) 2019-06-05
US20210253622A1 (en) 2021-08-19
US9481704B2 (en) 2016-11-01
AU2013232378B2 (en) 2017-09-28
KR20140135820A (ko) 2014-11-26
US20190016749A1 (en) 2019-01-17
HK1256856A1 (en) 2019-10-04
ES2709071T3 (es) 2019-04-15
CA2866381A1 (en) 2013-09-19
US11787832B2 (en) 2023-10-17
US10941177B2 (en) 2021-03-09
ES2878087T3 (es) 2021-11-18
EP3932931B1 (en) 2024-11-20
JP6242378B2 (ja) 2017-12-06
AU2013232378A1 (en) 2014-09-25
US20170114086A1 (en) 2017-04-27
EP2834258A1 (en) 2015-02-11
HK1207083A1 (en) 2016-01-22
PL2834258T3 (pl) 2017-07-31
EP3932931C0 (en) 2024-11-20
MD4496C1 (ro) 2018-02-28
ES2621217T3 (es) 2017-07-03
MX2014011009A (es) 2014-10-13
EP2834258B1 (en) 2017-01-04
EA201791916A1 (ru) 2018-07-31
EA201491548A1 (ru) 2015-02-27
CA2866381C (en) 2020-03-24
IL256397A (en) 2018-02-28
PT2834258T (pt) 2017-04-07
JP2019069986A (ja) 2019-05-09
EA028928B1 (ru) 2018-01-31

Similar Documents

Publication Publication Date Title
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
MD4602B1 (ro) Inhibitori ai virusului hepatic C
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501045B1 (en) Purine derivatives for the treatment of viral infections
PH12015501385A1 (en) Autotaxin inhibitors
IN2015DN01156A (enExample)
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX348229B (es) Derivados de 1,2,4-triazina para el tratamiento de infecciones virales.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2015011193A (es) Compuestos antivirales.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2015011198A (es) Compuestos antivirales.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
PH12014502065A1 (en) Vesicular formulations
PH12015502703A1 (en) Pharmaceutical compositions
MX2015011125A (es) Compuestos antivirales.
IN2014DN10683A (enExample)
TN2013000327A1 (en) Novel heterocyclic derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2018 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20170201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2022 BY CPA GLOBAL

Effective date: 20210128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2023 BY CPA GLOBAL

Effective date: 20220128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2024 BY CPA GLOBAL

Effective date: 20230127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250123